Callum P Mutch

115. The Yeasts: PCP/Pneumocytis jirovecii - ID:IOTS - Infectious Disease Insight Of Two Specialists Listen to this Pretty Comprehensive Pod on PCP. Alyssa and Callum cover:EpidemiologyTaxonomy (PCP vs PJP?)Diagnosis TreatmentNote this pod episode also includes some Positively Jolly Puns on...

call it PCP - you might come across as a relic

call it PJP - you may seem cleverish

either way, don't call it PCP-pneumonia or PJP-pneumonia - you will come across as redundant redundant

this @idiots-pod.bsky.social is a great review of the clinical aspects of pneumocystis infections.

#idsky

Consultant in Medical Microbiology :Various sites

Edinburgh is such a great place to live and work. Particularly in this sunny may.

Want to work here too (as a med micro +/- ID consultant)?

Well, check out this job advert: apply.jobs.scot.nhs.uk/Job/JobDetai...

< 72 h from launch → 48 placebo / active-controlled vaccine RCTs logged - now including all 5 COVID trials

1.43 M participants

Crowd-powered, freely accessible evidence that buries the “never placebo-tested” myth.

Browse or drop a PMID 👇
bit.ly/3EuYzqI

cc @bradspellberg.bsky.social

Impact of early infectious diseases consultation on the management of central line-associated bloodstream infection: a propensity score weighting retrospective cohort study - BMC Infectious Diseases Background Central line-associated bloodstream infection (CLABSI) is an important healthcare-associated infection, particularly in the intensive care unit (ICU). This study aimed to investigate the im...

Two hospital 🇰🇷 retrospective cohort study of ID consult and CLABSIs in the ICU

ID consults associated with:
-faster catheter removal
-more targeted antimicrobials

bmcinfectdis.biomedcentral.com/articles/10....

#IDSky

Penicillin Susceptible Staphylococcus aureus IS REAL!

"this is all just part of my CPD record"

Seems like a good catchphrase

Dr Neil Stone talking about social media & medicine in Vienna at ESCMID Global.

Now it’s @drneilstone.bsky.social talking about social media and medicine. “Bluesky is the dominant platform now.”
He said it. We will get him over to Bluesky for good! 💪🏼😉😁
#ESCMIDGlobal
#IDSky #MedSky

Why is this not happening #ESCMID2025

Was looking for this content and couldn't find it. I'm newly covering maxfax and ENT areas - couldn't see that much content. Any recommendations on conferences for these?

An example of a commercially available system below.

Strikes me that locally we have all this data but due to different systems there is no way to view as overview and so need to spend time creating summaries.

Consequence of digitised systems rather than digital transformation of care?

Challenge of clinical decision support systems is the lag of legislation from technological change. Overarching challenge in many areas #escmidglobal

There was more covered. Great session!

5. Update on enterococcal breakpoints. Including other species

Remember intrinsic vanc resistance ones! Cassesiflavus and gallinarum

Update on upcoming new anaerobic breakpoints - exciting but methodology difficult and so likely ref lab still

4. Answers to questions about dosing: Generally to use breakpoints table. But in IE breakpoints refer to ESC guidelines. Also rationale for no I category and assumption that highest dose always used

This seems less useful (to me) given issues in ESC dosing tables and clinical data on oral switch.

3. Breakpoints for cefepime-enmetazobactam (always a pleasure to try to spell) and aztreonam-avibactam

2. Stenotrophomonas updated breakpoints:
Updates CoT R breakpoint. ECOFFS for other agents. And a nice bonus on mechanisms of beta lactams resistance

EUCAST updates #ESCMIDglobal

1. Strep pneumonia updated algorithm:

Use oxacillin disk, if >20mm then report A to all beta lactams. If <20mm read benpen 1 unit disk. Great presentation showing data behind and how well differentiates S/I/R

I'm now not so sure about HECK Yes. Patrick Harris was suggesting we should be more reluctant to switch from piptaz etc to mero based on risk of ampC unless Enterobacter.

Will be interesting to see next ESCMID DTR GN guidelines and IDSA 2025 on AmpC.

But for purposes of teaching, yes - HECK yes!

Interesting chart. Some doubt about oral beta lactams for bacteraemia oral switch given time/MIC concerns and not meeting PD target in Enterobacterales with higher MICs. Was this addressed at all? Perhaps need an organism/MIC specific approach?

This is a sensible bar for IVOS #ESCMID2025

It is so complex but Patrick Harris's talk key - clinical data (so far) shows mostly need to worry about Enterobacter CC. So I will watch with interest but likely not teach on till we have more clinical!

We talk about inducible AmpC and derepression of AmpC inducible, but what are the mechanisms?

Well, it's complex, but depends on the species. AmpR and PBP4 key players. I might need to watch this talk again.... (and easily can because the conference platform is excellent)! #escmidglobal

Useful summary of inducible AmpC - strength of inducement and susceptibility to hydrolysis #escmidglobal

Just gotten my head round the public transport and #escmidglobal is almost done! Having pre-paid travel has made it very easy!

It's fantastic that the replay feature is so smooth. Definitely watching this one on catch-up!

#AI is here + will become key in #antimicrobialstewardship #AMS

Flagged by Prof Thursky @ncas.bsky.social at #ESCMID2025 #ESCMIDGlobal - this paper is a great blueprint for implementing AI in AMS programmes

Link: www.thelancet.com/journals/lan...

Essential diagnostics in low-resource settings

Sipho Dlamini, Dissou Affolabi, @makedasemret.bsky.social insights on
💥 Brain drain
💥 Lack of granularity in calls to improve
💡 Lessons of networks (echoing TB labs) in SSA

Current status: www.thelancet.com/journals/lan...

#ESCMIDGlobal #ESCMID2025

If first within 72hrs and negative, repeat

Then repeat at 14/7 to decide whether to extend

Not a huge amount of studies so only 2/14 PICO questions had good data to answer.

My learning points from @runningmadprof.bsky.social
- continue aciclovir at 14/7 if CSF remains positive or if not improved
- when to test for aciclovir resistance: if not improving/deteriorating
- when to test for anti-NMDA ab: relapse/recurrence
- single plex > multiplex for HSV diagnosis